UB Paderborn / Katalog / Suche / in CDI

1 – 25 von 101

Sortiert nach

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

The New England journal of medicine, 2018-07, Vol.379 (2), p.122-137

2018

Volltextzugriff (PDF)

Response to: Intrinsic subtype distribution should vary according to institutions

Breast (Edinburgh), 2020-12, Vol.54, p.350-350

2020

Volltextzugriff (PDF)

Comparison of Orally Administered Cannabis Extract and Delta-9-Tetrahydrocannabinol in Treating Patients With Cancer-Related Anorexia-Cachexia Syndrome: A Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial From the Cannabis-In-Cachexia-Study-Group

Journal of clinical oncology, 2006-07, Vol.24 (21), p.3394-3400

2006

Volltextzugriff (PDF)

Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial

Trials, 2018-12, Vol.19 (1), p.667-667, Article 667

2018

Volltextzugriff (PDF)

Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

Journal of clinical oncology, 2007-06, Vol.25 (16), p.2212-2217

2007

Volltextzugriff (PDF)

The multidisciplinary meeting: An indispensable aid to communication between different specialities

European journal of cancer (1990), 2006-10, Vol.42 (15), p.2459-2462

2006

Volltextzugriff (PDF)

Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution’s Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer

Breast (Edinburgh), 2020-06, Vol.51, p.120-126

2020

Volltextzugriff (PDF)

Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)

Breast (Edinburgh), 2021-12, Vol.60, p.98-110

2021

Volltextzugriff (PDF)

Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99

BMC cancer, 2020-02, Vol.20 (1), p.114-114, Article 114

2020

Volltextzugriff (PDF)

Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study

PloS one, 2015-04, Vol.10 (4), p.e0123435-e0123435

2015

Volltextzugriff (PDF)

CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial

The lancet oncology, 2008-02, Vol.9 (2), p.132-138

2008

Volltextzugriff (PDF)

Cetuximab in Combination With Chemoradiotherapy Before Surgery in Patients With Resectable, Locally Advanced Esophageal Carcinoma: A Prospective, Multicenter Phase IB/II Trial (SAKK 75/06)

Journal of clinical oncology, 2011-02, Vol.29 (6), p.626-631

2011

Volltextzugriff (PDF)

Eurythmy therapy versus slow movement fitness in the treatment of fatigue in metastatic breast cancer patients: study protocol for a randomized controlled trial

Trials, 2020-07, Vol.21 (1), p.612-12, Article 612

2020

Volltextzugriff (PDF)

Interleukin 7-expressing fibroblasts promote breast cancer growth through sustenance of tumor cell stemness

Oncoimmunology, 2018-04, Vol.7 (4), p.e1414129-e1414129

2018

Volltextzugriff (PDF)

Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology

JCO global oncology, 2021-12, Vol.7 (7), p.162-172

2021

Volltextzugriff (PDF)

Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy

Radiation oncology (London, England), 2019-09, Vol.14 (1), p.166-166, Article 166

2019

Volltextzugriff (PDF)

Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data

BMC cancer, 2019-09, Vol.19 (1), p.902-902, Article 902

2019

Volltextzugriff (PDF)

Team functioning across different tumour types: Insights from a Swiss cancer center using qualitative and quantitative methods

Cancer reports, 2022-08, Vol.5 (8), p.e1541-n/a

2022

Volltextzugriff (PDF)

Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)

BMC cancer, 2017-04, Vol.17 (1), p.265-265, Article 265

2017

Volltextzugriff (PDF)

Oncological care organisation during COVID-19 outbreak

ESMO open, 2020-08, Vol.5 (4), p.e000853, Article e000853

2020

Volltextzugriff (PDF)

Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores

Therapeutic advances in medical oncology, 2019-01, Vol.11, p.1758835918818351-1758835918818351

2019

Volltextzugriff (PDF)

Clinical Benefit and Quality of Life in Patients With Advanced Pancreatic Cancer Receiving Gemcitabine Plus Capecitabine Versus Gemcitabine Alone: A Randomized Multicenter Phase III Clinical Trial—SAKK 44/00–CECOG/PAN.1.3.001

Journal of clinical oncology, 2008-08, Vol.26 (22), p.3695-3701

2008

Volltextzugriff (PDF)

1 – 25 von 101

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(99)
Mit Volltextzugriff
(97)

Publikationsform

Artikel
(101)

Sprache

Englisch
(101)
Japanisch
(5)
Deutsch
(1)

Erscheinungsjahr

n.n

Thema

Science & Technology
(67)
Life Sciences & Biomedicine
(60)
Oncology
(57)
Humans
(56)
Female
(45)
Middle Aged
(38)
Aged
(30)
Adult
(27)
Breast Cancer
(26)
Chemotherapy
(23)
Male
(20)
Treatment Outcome
(20)
Tumors
(19)
Breast Neoplasms - Drug Therapy
(17)
Antineoplastic Combined Chemotherapy Protocols - Therapeutic Use
(16)
Breast Neoplasms - Pathology
(14)
Cancer Therapies
(14)
Quality Of Life
(14)
Biological And Medical Sciences
(13)
Medical Sciences
(13)

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Tailoring Adjuvant Endocrine Therapy for Premenopausal Breast Cancer

Response to: Intrinsic subtype distribution should vary according to institutions

Comparison of Orally Administered Cannabis Extract and Delta-9-Tetrahydrocannabinol in Treating Patients With Cancer-Related Anorexia-Cachexia Syndrome: A Multicenter, Phase III, Randomized, Double-Blind, Placebo-Controlled Clinical Trial From the Cannabis-In-Cachexia-Study-Group

Patient-reported outcomes with adjuvant exemestane versus tamoxifen in premenopausal women with early breast cancer undergoing ovarian suppression (TEXT and SOFT): a combined analysis of two phase 3 randomised trials

Tailored axillary surgery with or without axillary lymph node dissection followed by radiotherapy in patients with clinically node-positive breast cancer (TAXIS): study protocol for a multicenter, randomized phase-III trial

Gemcitabine Plus Capecitabine Compared With Gemcitabine Alone in Advanced Pancreatic Cancer: A Randomized, Multicenter, Phase III Trial of the Swiss Group for Clinical Cancer Research and the Central European Cooperative Oncology Group

The multidisciplinary meeting: An indispensable aid to communication between different specialities

Do YOU know the Ki-67 index of your breast cancer patients? Knowledge of your institution’s Ki-67 index distribution and its robustness is essential for decision-making in early breast cancer

Tailored axillary surgery in patients with clinically node-positive breast cancer: Pre-planned feasibility substudy of TAXIS (OPBC-03, SAKK 23/16, IBCSG 57-18, ABCSG-53, GBG 101)

Plasma HER2ECD a promising test for patient prognosis and prediction of response in HER2 positive breast cancer: results of a randomized study - SAKK 22/99

Standardization for Ki-67 assessment in moderately differentiated breast cancer. A retrospective analysis of the SAKK 28/12 study

Highlights of the EORTC St. Gallen International Expert Consensus on the primary therapy of gastric, gastroesophageal and oesophageal cancer – Differential treatment strategies for subtypes of early gastroesophageal cancer

CA 19-9 tumour-marker response to chemotherapy in patients with advanced pancreatic cancer enrolled in a randomised controlled trial

Cetuximab in Combination With Chemoradiotherapy Before Surgery in Patients With Resectable, Locally Advanced Esophageal Carcinoma: A Prospective, Multicenter Phase IB/II Trial (SAKK 75/06)

Eurythmy therapy versus slow movement fitness in the treatment of fatigue in metastatic breast cancer patients: study protocol for a randomized controlled trial

Interleukin 7-expressing fibroblasts promote breast cancer growth through sustenance of tumor cell stemness

Expected Medium- and Long-Term Impact of the COVID-19 Outbreak in Oncology

Skeletal muscle mass correlates with increased toxicity during neoadjuvant radiochemotherapy in locally advanced esophageal cancer: A SAKK 75/08 substudy

Long-term responders to trastuzumab monotherapy in first-line HER-2+ advanced breast cancer: characteristics and survival data

Team functioning across different tumour types: Insights from a Swiss cancer center using qualitative and quantitative methods

High thromboembolic event rate in patients with locally advanced oesophageal cancer during neoadjuvant therapy. An exploratory analysis of the prospective, randomised intergroup phase III trial SAKK 75/08

Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)

Oncological care organisation during COVID-19 outbreak

Predicting mortality and adverse events in patients with advanced pancreatic cancer treated with palliative gemcitabine-based chemotherapy in a multicentre phase III randomized clinical trial: the APC-SAKK risk scores

Clinical Benefit and Quality of Life in Patients With Advanced Pancreatic Cancer Receiving Gemcitabine Plus Capecitabine Versus Gemcitabine Alone: A Randomized Multicenter Phase III Clinical Trial—SAKK 44/00–CECOG/PAN.1.3.001

Suchergebnisse filtern